Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Galapagos, Roche End Fibrosis Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Galapagos, Roche End Fibrosis Alliance

Galapagos regains rights to all assays and targets

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Galapagos NV and Roche have agreed to end their alliance in fibrosis. Galapagos will receive a payment of $7.5 million for work completed in 2012. Galapagos regains worldwide rights to all fibrosis assays and the targets discovered in the alliance. The company received a total of approximately $20.8 million in upfront and milestone payments from Roche under the collaboration.
 
“We regret that Roche ended the alliance due to a strategic change, but the good news is that all assets have returned to Galapagos,” said Onno van de Stolpe, chief executive officer of Galapagos. “Our plan is to find another partner to continue the search for compounds against these debilitating diseases.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics